Status:
COMPLETED
Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder
Lead Sponsor:
Mclean Hospital
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Borderline Personality Disorder
Eligibility:
All Genders
18-64 years
Phase:
PHASE4
Brief Summary
This study investigates the hypothesis that instability in mood in patients with borderline personality disorder will respond the mood stabilizing medication lamotrigine.
Detailed Description
Affective instability is one of the most prominent symptoms in borderline personality disorder. Currently there are no prospective studies of treatment of this symptom with mood stabilizing medication...
Eligibility Criteria
Inclusion
- Clinical Diagnosis of Borderline Personality Disorder with high levels of emotional instability
Exclusion
- Clinical diagnosis of Bipolar Disorder
- Clinical diagnosis of psychiatric disorder related to general medical condition
- Clinical diagnosis of substance abuse disorder within the last 60 days
- Clinical diagnosis of psychotic disorder
- Previous treatment with lamotrigine
- Pregnancy or nursing
- Currently hospitalized
- Active suicidal or homicidal ideation
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00634062
Start Date
December 1 2004
End Date
September 1 2007
Last Update
March 12 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McLean Hospital
Belmont, Massachusetts, United States, 02478